TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Newborn Vitamin A Supplementation Versus Placebo in Improving Child Survival (NeoVitA Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consent to participate~* All births in the study area that are contacted by enrolment team within the eligible age window~Exclusion Criteria:~* Unable to feed on offering feeds, as reported by the mother~* Mother does not intend to stay in the study area for at least 6 months

- Gender: ALL
- Minimum Age: 2 Hours
- Maximum Age: 72 Hours
- Healthy Volunteers: t

Study Arms:
- Vitamin A (Type: EXPERIMENTAL): Vitamin A capsules have retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules contain minute amounts of vitamin E in soybean oil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Benidipine-based Comparison of Angiotensin Receptors, β-blockers, or Thiazide Diuretics in Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients who are required a combination therapy with sitting systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg.~* Outpatients aged over 40 years and less than 85 years (inclusive), regardless of sex.~* Previously untreated patients or patients who are on other therapy, which can be converted to 4mg of benidipine.~* Patients who can be treated with benidipine, angiotensin receptor blockers, β-blockers, and thiazide diuretics.~Exclusion Criteria:~* Seated systolic blood pressure ≥ 200 mmHg or seated diastolic blood pressure ≥ 120 mmHg.~* Secondary hypertension.~* Type I diabetes mellitus or type 2 diabetes on insulin treatment.~* History of cerebrovascular disorder, myocardial infarction, angina pectoris, coronary angioplasty or coronary artery bypass graft surgery within 6 months prior to enrolment in the study.~* Heart failure (New York Heart Association \[NYHA\] functional classification II, III or IV).~* Chronic atrial fibrillation or atrial flutter.~* Congenital heart disease or a history of rheumatic heart disease.~* Severe peripheral arterial disease (Fontaine Class II, III or IV).~* Serious liver dysfunction (AST or ALT ≥100 IU / l).~* Serious renal dysfunction (serum creatinine ≥ 2mg/dl).~* History of malignancy 5 years prior to study entry.~* Pregnancy.~* Compliance rate \< 70% assessed by a patient interview.~* Known hypersensitivity or contraindication to benidipine, angiotensin receptor blockers, β-blockers, and thiazide diuretics.~* Other serious illness or significant abnormalities that the investigator judges inappropriate for the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- angiotensin receptor blockers (Type: ACTIVE_COMPARATOR): benidipine+angiotensin receptor blockers, titlation scheme
- β-blockers (Type: ACTIVE_COMPARATOR): benidipie+β-blockers, titlation scheme
- thiazide diuretics (Type: ACTIVE_COMPARATOR): benidipine+thiazide diuretics, titlation scheme

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 and bOPV 1,3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Infants \> 2.5 kg birth weight~* Immediate cry~* No neonatal IMCI danger signs~* Not planning to travel away during entire the study period (birth-102 days)~Exclusion Criteria:~* High-risk newborns will be excluded, as well as newborns requiring hospitalization~* Birth weight below 2.5 kg~* Cry \>2 minutes~* With any neonatal IMNCI danger signs~* Residence \>30 km from study site~* Family is planning to be absent during the birth - 102 day study period.~* A diagnosis or suspicion of immunodeficiency disorder (either in the participant or in a member of the immediate family - e.g. several early infant deaths, household member on chemotherapy) will render the newborn ineligible for the study.

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 24 Hours
- Healthy Volunteers: t

Study Arms:
- mOPV1- Arm A (Type: EXPERIMENTAL): Arm A will be administered a second dose of mOPV1 seven days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at day 79.
- mOPV1- Arm B (Type: EXPERIMENTAL): Arm B will be administered a second dose of mOPV1 fourteen days after after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 86 days.
- mOPV1-Arm C (Type: EXPERIMENTAL): Arm C will receive the second dose of mOPV1 thirty days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 102 days.
- Arm D- bOPV1,3 (Type: EXPERIMENTAL): Arm D will be administered a second dose of bOPV1,3 thirty days after the 42 day bOPV1,3 index dose.Second dose of tOPV2 will be given at day 102.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent must be obtained before any assessment is performed~* Diagnosis of psoriatic arthritis classified by Classification criteria for psoriatic arthritis (CASPAR) criteria~* Active spinal disease defined by Bath ankylosing spondylitis disease activity index (BASDAI) score ≥ 4~* Spinal Pain visual analog scale (VAS) ≥ 40 (on a VAS 100 scale)~* Inadequate Response to at least 2 non-steroidal anti-inflammatory drugs over a 4 weeks period~Exclusion Criteria:~* History of exposure to other IL-17 or IL-23 inhibitor biologic drug~* History of exposure to previous biologic disease modifying anti-rheumatic drugs (DMARDs) (Tumor necrosis factor (TNF) blockers or Ustekinumab)~* Current treatment with disease modifying anti-rheumatic drugs (DMARDs) other than Methotrexate~* Subjects taking high potency opioid analgesics (e.g. methadone, hydromorphone, morphine)~* Chest X-ray or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician~Other protocol-defined inclusion and exclusion criteria may have applied.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AIN457 150mg (Type: EXPERIMENTAL): Secukinumab dose amount 1 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 1 sc injection every 4 weeks for remaining 44 weeks
- AIN457 300mg (Type: EXPERIMENTAL): Secukinumab dose amount 2 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 2 sc injection every 4 weeks for remaining 44 weeks
- AIN457 Placebo (Type: PLACEBO_COMPARATOR): Placebo sc injection weekly for 4 weeks and at week 8, followed by Secukinumab 150 mg or 300 mg sc injection every 4 week for remaining 40 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Firstly diagnosed metastatic nasopharyngeal carcinoma patients~* Disease controlled after 4-6 cycles of palliative chemotherapy with taxol,cisplatin and capecitabine~* Eastern Cooperative Oncology Group (ECOG) 0-2~* Life expectation at least 12 weeks~* No systemic chemotherapy within 6 months, except for induction chemotherapy or concurrent chemotherapy~* With at least one measurable lesion~* Enough blood test~* Signed informed consent~Exclusion Criteria:~* Sever heart disease~* HIV infection~* Sever infection~* Brain metastasis, except received radical therapy 6 months ago and stable in 4 weeks~* Allogeneic organ transplantation~* Malignancy other than nasopharyngeal carcinoma, except:cervical carcinoma in situ, cured basal cell carcinoma,bladder cancer of Ta,Tis or T1, or any cured cancer for at least 3 years~* Pregnancy or breast feeding~* Difficulty in swallowing~* Received other test drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- maintenance capecitabine (Type: EXPERIMENTAL): maintenance capecitabine plus best supportive care(BSC)
- best supportive care (Type: OTHER): Best supportive care and following-up every 6-8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have a VA medical center primary care provider;~* Failed first line diet and exercise recommendations;~* In stable health by screening physical and lab tests;~* Agrees to make regular visits per study protocol;~* Has access to telephone;~* Body mass index (BMI) \> or = 27 with obesity-related illness OR BMI \> or = 30 with no risk factors;~* No contraindications to Orlistat;~* Not pregnant or breast-feeding;~* No serious mental health illness such as dementia or schizophrenia;~* No use of a weight loss therapy in the month prior to screening.~Exclusion Criteria:~* No VAMC primary care provider~* Unable to attend regular study visits~* No access to telephone~* BMI \< 27~* Contraindications to Orlistat~* Pregnancy, breast feeding or planning to become pregnant~* Unstable mental health illness~* Use of a weight loss therapy in the month prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: t

Study Arms:
- Low Carbohydrate Ketogenic Diet (Type: EXPERIMENTAL): Participants receive dietary counseling over 48 weeks aimed at helping them to lower starch and sugar intake.
- Low-Fat Diet plus Orlistat (Type: ACTIVE_COMPARATOR): Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake, and additionally receive Orlistat taken 3 times daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Dexamethasone on Rebound Pain in Patients Receiving Ilioinguinal and Iliohypogastric Nerve Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-II~* Having signed a written informed consent form~* Scheduled for unilateral primary hernia repair Lichtenstein style (open surgery with insertion of mesh) under general anesthesia~Exclusion Criteria:~* Chronic opioid use (more than one month of 60 mg of oral morphine equivalents daily)~* Contraindications to peripheral nerve blocks including localized infection, coagulopathy, or allergy to local anesthetics~* Stomach ulcer~* Severe obesity (body mass index \> 35 kg/m2)~* Uncontrolled Diabetes~* Psychiatric disorders~* Systemic steroid use~* Neuropathic disorder~* Can not communicate in Turkish

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group Dexa (Type: ACTIVE_COMPARATOR): After induction of general anesthesia, an ultrasound-guided block of the ilioinguinal and iliohypogastric nerve block will be performed using 20 ml 0.5% bupivacaine. 5 mg dexamethasone in a 50 ml syringe containing normal saline will be infused within 15 minutes. A multimodal analgesia regimen will be applied postoperatively.~The syringe will be prepared by a nurse outside the research team and the study participants, care providers, and data collectors will be blinded to the allocation throughout the study
- Group S (Type: SHAM_COMPARATOR): After induction of general anesthesia, an ultrasound-guided block of the ilioinguinal and iliohypogastric nerve block will be performed using 20 ml 0.5% bupivacaine. 50 mL normal saline in a 50 ml syringe will be infused within 15 minutes. A multimodal analgesia regimen will be applied postoperatively.~The syringe will be prepared by a nurse outside the research team and the study participants, care providers, and data collectors will be blinded to the allocation throughout the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficiency, Safety and Portability of Neovasculgen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age more than 40 years;~* a history of stable claudication for at least 3 months;~* stage 2 to 3 chronic ischemia according to Fontaine classification (modified by A. V. Pokrovsky);~* presence of hemodynamically significant (stenosis \>70% and/or occlusion) diffuse lesions of the interior and (or) posterior tibial arteries (distal lesion);~* voluntary informed consent signed and dated by the patient.~Exclusion Criteria:~* chronic lower limb ischemia of nonatherosclerotic genesis; stage 4 chronic ischemia according to Fontaine classification modified by A. V. Pokrovsky (ischemic ulcers and necrotic lesions);~* severe concomitant pathology with life expectancy \<1 year;~* infectious diseases, history of cancer, or suspected malignancy;

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Neovasculgen (Type: EXPERIMENTAL): DNA encoding the 165-amino-acid isoform of human vascular endothelial growth factor (pCMV - VEGF165)
- Control (Type: NO_INTERVENTION): Control therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Genetically confirmed diagnosis of Alagille syndrome~* History of significant pruritus as measured by the Albireo Observer or Patient Reported Outcome instrument~* Elevated serum bile acid level~Key Exclusion Criteria:~* History or ongoing presence of other types of liver disease (eg. biliary atresia, progressive familial intrahepatic cholestasis, hepatocellular carcinoma)~* History of liver transplant, or a liver transplant is planned within 6 months of randomization~* ALT \>10× upper limit of normal (ULN) at screening~* Total bilirubin \>15 × ULN at screening~* Patient suffers from uncontrolled, recalcitrant pruritic condition other than Alagille syndrome

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Odevixibat (A4250) (Type: EXPERIMENTAL): Capsules for oral administration once daily for 24 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Capsules for oral administration (to match active) once daily for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or females 12 years or older~* History of persistent bronchial asthma for at least 6 months~* Documented use of bronchodilators (short acting only) only or methylxanthines for at least 1 month before screening~* At screening, FEV1 60 to 90% of predicted. Reversibility of FEV1 by at least 12% post-bronchodilator~* Be able to use oral inhalers~* Non-smokers~Exclusion Criteria:~* History of life-threatening asthma~* Other pulmonary diseases~* URI within 4 weeks before screening~* Use of systemic steroids within 6 months before screening. Use of inhaled steroids within 30 days before screening. More than 2 in-patient hospitalizations or ER visits due to asthma exacerbations in the prior year before screening~* Pregnant or breast-feeding females~* Females of child-bearing potential not using adequate means of birth control~* Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease~* Abnormal clinical laboratory parameters that would limit participation in the study or interfere with interpretation of study results~* History of drug or alcohol abuse~* Treatment with any investigational product within 30 days prior to study entry

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Arimidex in Gynecomastia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent/assent (as per local requirements), males aged 11-18 yrs. (after his 10th and prior to 19th birthday), gynecomastia, one breast measuring ≥ 2 cm in diameter (by ultrasound or caliper measurement) that has not decreased during the prior 3 month period by medical history and has been present for 12 months or less (date of onset based on best estimate of treating physician after discussion with patient and or patient's parent/guardian), normal renal liver and thyroid function, no evidence of hormone producing tumor, no evidence of hypogonadism or androgen resistance.~Exclusion Criteria:~* Patients who have been given medications known to cause gynecomastia within the previous 6 months, involvement in the planning and conduct of the study (includes AZ staff and investigative site staff), previous enrollment in the present study, investigators opinion patient would be unable to comply with study protocol.

- Gender: MALE
- Minimum Age: 11 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of treatment resistant partial epilepsy;~* History of epilepsy for at least 2 years;~* Have at least 3 simple partial with motor component, complex partial or secondarily generalized seizures per month with no consecutive 21 day seizure free period.~* Currently treated on a stable dose of :~  * 1 - 3 AED's for at least 12 weeks prior to randomization.~ * VNS will not be counted as AED; however the parameters must remain stable for at least 4 weeks prior to baseline.~ * Benzodiazepines taken at least once per week for epilepsy, or for anxiety or sleep disorder, will be counted as 1 AED. Therefore only a maximum of two additional approved AEDs will be allowed.~Exclusion Criteria:~1. A history of alcoholism, drug abuse, or drug addiction within the past 2 years.~2. Subject has had status epilepticus within past 1 year.~3. Subject has had greater than 2 allergic reactions to an AED or one serious hypersensitivity reaction to an AED.~4. Subjects taking felbamate with less than 18 months continuous exposure.~5. Subjects receiving phenytoin, phenobarbitone or metabolites of these drugs.~6. No active suicidal plan/intent or active suicidal thoughts in the past 6 months.~7. History of suicide attempt in the last 2 years; not more than 1 lifetime suicide attempt.~8. Subject meets criteria for current major depressive episode (within 6 months).~9. Use of intermittent rescue benzodiazepines more than once/month (1-2 doses in a 24-hour period is considered one rescue) in the one month period prior to Visit 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- YKP3089 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete